<DOC>
	<DOCNO>NCT02940392</DOCNO>
	<brief_summary>Evaluate effect NxThera BPH Rezum System prostate tissue subject suffer LUTS symptom secondary benign prostatic hyperplasia ( BPH ) .</brief_summary>
	<brief_title>Rezum FIM Optimization</brief_title>
	<detailed_description>Subjects BPH symptom treat Rezum device range thermal energy ( measure calorie output ) optimize set maximum lesion size minimal intra post-procedure discomfort . Lesion size ablate tissue resorption rate follow post-procedure 1 week , 1 month , 3 month , 6 month .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Adenoma</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<criteria>1 . Male subject &gt; 45 year age symptomatic / obstructive symptom secondary BPH require invasive intervention . 2 . IPSS score ≥ 15 . 3 . Qmax : Peak flow rate ≤ 15 ml/sec . 4 . Postvoid residual ( PVR ) &lt; 300 ml . 5 . Prostate transverse diameter &gt; 30 mm . 6 . Prostate volume 20 120 gm . 7 . Voided volume ≥ 125 ml . 8 . Subject able complete study protocol opinion Principal Investigator . 9 . Subject must willing undergo procedure without anesthesia . 1 . History illness surgery opinion Principal Investigator may confound result study . 2 . Presence penile implant . 3 . Any prior minimally invasive intervention ( e.g . TUNA , Laser , Microwave ) surgical intervention symptom BPH . 4 . Currently enrol another clinical trial . 5 . Confirmed suspected malignancy prostate bladder . 6 . Previous rectal surgery ( hemorrhoidectomy ) history rectal disease . 7 . Previous pelvic irradiation radical pelvic surgery . 8 . Documented active urinary tract infection culture bacterial prostatitis within last year document culture ( UTI define &gt; 100,000 colony per ml urine midstream clean catch catheterization specimen ) . 9 . Neurogenic bladder sphincter abnormality . 10 . Urethral stricture , bladder neck contracture muscle spasm . 11 . Bleeding disorder ( note use antiplatelet medication exclusion criterion ) . 12 . Subjects interested maintain fertility . 13 . Use concomitant ( recent ) medication include follow : 1 . Beta blocker , antihistamine , anticonvulsant , antispasmodic within 1 week treatment , unless document evidence stable dose last 6 month ( e.g. , dose change ) . 2 . Alpha blocker , antidepressant , anticholinergic , androgen , gonadotropinreleasing hormonal analog within 2 week treatment . 3 . 5alpha reductase inhibitor within last 6 month 14 . Subject unable unwilling go `` washout '' period medication prior treatment . 15 . Subject chronic urinary retention . 16 . Significant urge incontinence . 17 . Poor detrusor muscle function . 18 . Neurological disorder might affect bladder sphincter function . 19 . Bladder stone . 20 . Renal impairment . 21 . In opinion Principal Investigator , subject able adequately tolerate rigid cystoscopytype procedure . 22 . Unable unwilling sign Informed Consent Form ( ICF ) and/or comply require followup requirement . 23 . Any cognitive disorder interferes precludes subject directly accurately communicate Principal Investigator regard study . 24 . Peripheral arterial disease intermittent claudication Leriches Syndrome ( i.e. , claudication buttock perineum ) . 25 . Biopsy prostate within 30 day prior Rezūm procedure .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Rezum</keyword>
</DOC>